唑来膦酸治疗乳腺癌骨转移的相关研究进展  

Research Progress of Zoledronic Acid in the Treatment of Bone Metastasis of Breast Cancer

作　　者：何新梅 刘媛媛[1] He Xinmei;Liu Yuanyuan(Department of Radiology and Chemotherapy,The First Affiliated Hospital of Jiamusi University,Jiamusi 154000,China)

机构地区：[1]佳木斯大学附属第一医院放化疗科,黑龙江佳木斯154000

出　　处：《广东化工》2022年第8期109-110,共2页Guangdong Chemical Industry

摘　　要：目前乳腺癌已经成为我国育龄女性最常见的恶性肿瘤之一。远处肿瘤转移基因是肿瘤患者早期引起肿瘤死亡的重要发病原因。骨转移是晚期女性乳腺癌最常出现的一种并发症。最终大约有80%的晚期乳腺癌患者发生骨转移,骨转移疾病可以直接导致乳腺癌患者晚期出现一系列的骨转移相关疾病事件(SRE)。唑来膦酸为双膦酸盐的第三代药物,它是一种特异性地作用于骨的二磷酸化合物,现有研究已证实该药品主要是通过抑制破骨细胞活性和诱导破骨细胞凋亡来抑制骨吸收防止骨转移。本文将对唑来膦酸防治女性乳腺癌骨转移相关研究进展进行综述。At present, breast cancer has become one of the most common malignant tumors in women of childbearing age in China. Distant tumor metastasis genes are an important cause of early tumor death in tumor patients. Bone metastasis is one of the most frequent complication of breast cancer in advanced women.Bone metastases will eventually occur in about 80 % of patients with advanced breast cancer, and bone metastatic disease can directly lead to a series of bone metastasis-related disease events(SRE) in advanced breast cancer patients. Zoledronate is the third-generation drug of bisphosphonate, which is a diphosphate compound acting specifically on bone, and existing studies have demonstrated that this drug suppresses bone resorption to prevent bone metastasis mainly by inhibiting osteoclast activity and inducing osteoclast apoptosis. The progress of the prevention of bone metastasis in breast cancer in women will be reviewed.

关 键 词：唑来膦酸 二磷酸化合物 晚期乳腺癌(MBC) 骨转移 双膦酸盐 地诺单抗 

分 类 号：R737.9[医药卫生—肿瘤]